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Rationale: Molecular mimicry theory (MMT) suggests that epitope mimicry between
pathogens and human proteins can activate autoimmune disease. Group A streptococci
(GAS) mimics human cardiac myosin in rheumatic heart disease (RHD) and coxsackie
viruses (CX) mimic actin in autoimmune myocarditis (AM). But myosin and actin are
immunologically inaccessible and unlikely initial targets. Extracellular cardiac proteins that
mimic GAS and CX would be more likely.
Objectives: To determine whether extracellular cardiac proteins such as coxsackie and
adenovirus receptor (CAR), beta 1 adrenergic receptor (B1AR), CD55/DAF, laminin, and
collagen IV mimic GAS, CX, and/or cardiac myosin or actin.
Methods: BLAST 2.0 and LALIGN searches of the UniProt protein database were employed
to identify potential molecular mimics. Quantitative enzyme-linked immunosorbent assay
was used to measure antibody cross-reactivity.
Measurements: Similarities were considered to be significant if a sequence contained at
least 5 identical amino acids in 10. Antibodies were considered to be cross-reactive if the
binding constant had a K -9d less than 10 M.
Main results: Group A streptococci mimics laminin, CAR, and myosin. CX mimics actin
and collagen IV and B1AR. The similarity search results are mirrored by antibody cross-
reactivities. Additionally, antibodies against laminin recognize antibodies against collagen
IV; antibodies against actin recognize antibodies against myosin, and antibodies against
GAS recognize antibodies against CX. Thus, there is both mimicry of extracellular proteins
and antigenic complementarity between GAS-CX in RHD/AM.
Conclusion: Rheumatic heart disease/AM may be due to combined infections of GAS
with CX localized at cardiomyocytes that may produce a synergistic, hyperinflammatory
response that cross-reacts with laminin, collagen IV, CAR, and/or B1AR. Epitope drift shifts
the immune response to myosin and actin after cardiomyocytes become damaged.
Keywords: antigenic complementarity, epitope drift, hidden antigens, theory, co-infection, group A streptococci,
coxsackie virus, hyperinflammation
INTRODUCTION
The purpose of this study is to re-evaluate the role of molecular
mimicry (MM) in rheumatic heart disease (RHD) and autoim-
mune myocarditis (AM) in light of serious questions concerning
its adequacy to explain autoimmune disease.
The basic idea behind molecular mimicry theory (MMT) is
that microbes evolve to evade the immune system through selec-
tion for proteins that mimic those of their host (1–5). One result
of this mimicry is cross-reactivity between pathogens and host
proteins that can trigger autoimmune disease. Several pathogens
have been associated clinically and epidemiologically with RHD
and AM: group A streptococci (GAS) [reviewed in Ref. (6, 7)];
coxsackie viruses (CX) [reviewed in Ref. (8, 9)]; Trypanosoma
cruzi (10); Chlamydia (11, 12), perhaps varicella zoster virus (13),
cytomegalovirus (14), hepatitis C virus (15), ECHO virus, aden-
ovirus, Epstein–Barr virus, and parvovirus B19 (16–19). It was
established several decades ago that three of these pathogens,
GAS, T. cruzi, and CX induce immunological responses that
cross-react with cardiac proteins (20–26). The demonstration that
GAS induced myosin-specific antibodies that were associated with
organ-specific disease and that RHD could be induced using car-
diac myosin or its mimic, the M protein of GAS, seemed to clinch
the case for MM as the cause of autoimmune disease. Concomi-
tant development of animal models of AM using CX infections
(27, 28) further substantiated MMT.
Serious questions, however, have been raised over the past few
years as to the adequacy of MMT to explain autoimmune diseases
in general and RHD and AM in particular. If MM is sufficient to
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induce autoimmune disease, then one would expect much higher
rates of disease than are observed. All of the infections associated
with onset of RHD and AM are very common, yet few infections
result in autoimmune disease. It is estimated that 14% of the pop-
ulation has genes associated with increased RHD risk (7, 29), most
people contract one or more GAS or CX infections, yet only 1 in
5000 people who develop GAS pharyngitis go on to develop RHD
(30, 31) while only about 1 in 500 people who develop a coxsackie
viral infection develop AM (32). The rates of RHD and AM are
thus far smaller than would be predicted based on MMT.
Another problem is that according to many investigators, very
little evidence exists for MM playing a role in human disease (33–
35). Fourneau et al. concede that the best human data exist for
RHD and Guillain–Barre syndrome (GBS) but caution that even
for RHD and GBS, it had not been demonstrated that the initial
immune response to the target tissues in either disease is actually
due to MM; it was quite possible that infection results in release
of hidden antigens such as myosin and actin that add to, but do
not induce, disease. Fujinami et al. has recently expressed reserva-
tions about the theory he himself helped to develop (36), noting
that all current animal models based on MMT require adjuvants,
in addition to the molecular mimic, to induce a hyperinflam-
matory response. It is not, for example, possible to induce RHD
in animals using purified M proteins from GAS; experimental
RHD requires the addition of Freund’s complete adjuvant – no
other adjuvant has been found to work (32). The role of the
adjuvant in MMT has remained unresolved but strongly sug-
gests that mimicry is insufficient to induce autoimmune disease.
Fujinami notes that molecular mimics may require bystander-
induced damage to initiate disease by releasing hidden antigens
(36), a position that has urged more strongly by Tandon et al.
(37). The applicability of MMT to Chagas disease has also been
hotly debated (38).
The major problem faced by MMT is that while molecular or
epitope mimicry may be necessary, it is not clear that it is suffi-
cient to explain autoimmune disease. In RHD/AM, most of the
reported mimicry between pathogens and host proteins involve
intracellular host proteins such as cardiac myosin (6, 26, 39) and
actin (40). These proteins should not be accessible to the immune
system as long as cardiac tissue is intact. Neu et al. (41) have, in fact,
demonstrated that anti-myosin antibodies do not recognize intact
myocardiocytes, that the myosin antibody titer does not correlate
with onset of experimental autoimmune myocarditis (EAM), and
that myosin antibodies are not sufficient to induce EAM in a pas-
sive transfer model. In addition, as Reddy et al. (42) has argued, if
myosin were the major autoantigen inducing RHD and AM, then
one would expect that patients with cardiac damage would develop
these diseases at much higher rates than other patients, yet it has
been demonstrated that patients who contract rheumatic fever or
have cardiac infarcts, bypass surgeries, and heart transplants do
not develop RHD or AM despite producing anti-myosin antibod-
ies (43–46). This problem is exacerbated by evidence that GAS and
CX induce antibodies against many non-cardiac proteins and that
non-pathogens mimic myosin as well as do GAS and CX (47–52).
This produces the conundrum that the existence of mimicry is not
sufficient to induce disease while non-pathogens, under the right
conditions, can! In fact, in EAM, there is no immune response
to cardiac myosin initially; anti-myosin antibodies develop later
in the disease process (41, 53–55). An autoimmune response to
some cardiac protein other than myosin must come first, so there
must be some way of targeting heart tissue other than GAS-myosin
mimicry. Why, then, are myosin antibodies so well correlated with
RHD and AM pathogenesis and how does the immune system
“know” to target tissues that contain antigens that it cannot “see”
before it has damaged that tissue? Has the focus on GAS mimicry
of myosin blinded us to other forms of epitope mimicry against
cell surface targets such as the beta 1 adrenergic receptor (B1AR)
that has been identified as a possible autoimmune target in dilated
cardiomyopathies (DCM) (56–59)?
Despite the many problems that clearly challenge MMT, it
would be a mistake to “throw the baby out with the bath water,”
as the saying goes. Science does not progress by discarding the
knowledge acquired by inadequate theories but by incorporating
that knowledge into a more comprehensive theory. Each of the
problems just enumerated helps to define the kinds of factors that
need to be added to MMT to produce a more complete and effec-
tive theory of autoimmune disease. Davies (33) and Fourneau
et al. (35) pointed out that antigens such as myosin and actin
that dominate the late immune response in RHD/AM need not
be the antigens that initiate autoimmunity; epitope spreading
may occur in which one host protein is the initial target of an
autoimmune response, the result of which is release of hidden
host antigens that then come to dominate subsequent autoimmu-
nity. Clues exist as to what proteins might be the initial targets in
RHD/AM. GAS utilize collagen type IV in the basement mem-
branes of cardiac tissue as binding sites (37, 60–62). GAS are
also known to target specific tissues by means of cell surface
proteins Cnm and Cbm that bind specifically to collagen type
1 and Cbm subtypes are found preferentially in heart biopsies
from patients with endocarditis (63). In addition, GAS can use
a hemoprotein receptor, (Shr), as well as an extracellular protein
factor (Epf or PrtF), to bind to laminin and fibronectin on target
cells (64–66). Similarly, type B CX and sub-group type C ade-
noviruses use the coxsackie and adenovirus receptor (CAR) and
the CD55 or decay-accelerating factor for complement (DAF) to
target cells [reviewed in Ref. (67)] but other extracellular pro-
teins are clearly involved since antibodies against these receptors,
and soluble receptors themselves, are not sufficient to prevent
CX infection of cardiomyocytes (68, 69). Another possible target
might be the beta 1 adrenergic receptor (B1AR), which has already
been implicated in DCM (56–59). In short, one might expect
that extracellular proteins such as laminins, collagens, fibronectin,
DAF, CAR, and B1AR would be much more likely than intracel-
lular proteins, such as myosin, actin, or troponin, to be initial
targets of an autoimmune response producing cardiomyocyte
damage.
The purpose of this paper is to explore the possibility that extra-
cellular cardiac proteins employed by GAS and CX as receptors
may be the initial targets of the autoimmune response in RHD/AM
and that cardiac myosin and actin are actually secondary targets
that help sustain the autoimmune response. More particularly, we
investigate whether GAS and CX may mimic extracellular cardiac
proteins and whether epitope drift may then shift the autoimmune
response from external to internal protein targets. Two types of
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Table 1 | Summary of results of BLAST 2.0 similarity searches comparing the human proteins (left) with the pathogens (top).
CX 6 CX>60 MP1 6 MP1>60 MP2 6 MP2>60 HCV 6 HCV>60 PV6 PV>60
Actin 3 3 3 0 1 0 2 0 6 0
Collagen I 8 0 1 1 1 1 15 6 5 1
Collagen IV 6 1 2 0 2 0 18 13 6 1
Troponin 5 0 5 1 9 1 2 0 2 1
Myosin 14 2 29 50 35 50 7 2 7 4
Laminin 1 8 4 3 4 4 3 1 0 9 2
Laminin 2 10 6 4 17 5 12 2 6 6 5
Laminin 3 4 3 5 11 7 11 4 3 8 3
Laminin 4 4 0 6 2 4 3 4 3 10 0
Laminin 5 10 2 7 8 5 8 2 5 3 1
CD55 5 0 0 0 0 0 7 0 6 1
CXAR 3 1 1 0 1 0 5 0 1 0
PVR 4 1 0 0 0 0 6 1 6 1
CD81 1 0 0 0 0 0 3 0 2 0
CLDN1 2 0 0 0 0 0 3 0 1 0
CD20 2 0 5 0 3 0 6 0 2 0
B1AR 1 1 0 0 0 0
HepC * * 3 0 3 0
PV * * 0 0 0 0
Actin is cardiac actin; Myosin is cardiac myosin; CD55 is also known as DAF, the complement decay-accelerating factor used by coxsackie viruses as a receptor;
CXAR is the coxsackie and adenovirus receptor; PVR is the poliovirus receptor; CD81, a hepatitis C virus receptor; CLDN1 is claudin 1, a cell adhesion molecule;
CD20, a B lymphocyte antigen; B1AR is the beta 1 adrenergic receptor, an autoantibody target in cardiomyopathies. CX is coxsackie B3 virus; MP1 and MP2 are two
versions of the group A streptococcal M protein; HCV is hepatitis C virus; PV is poliovirus. In the columns labeled CX, etc. followed by “6” are listed the number of
similar sequences that contained at least 6 identical amino acids in a sequence of 10. In the columns labeled CX, etc. followed by “>60” are listed the number of
similar sequences that had an E value of greater than 60. E values greater than 60 are generally rare and usually indicate lengthy and statistically significant regions
of similarity. The most significant sets of similarities as determined by a combination of both identical amino acids and E values are highlighted in shades of gray
(significant), dark gray (very significant), or black (extremely significant) as determined by comparison with the rest of the study results.
methods are employed. The first involves similarity searches to
determine whether extracellular cardiac proteins mimic GAS and
CX. The second involves the use of quantitative enzyme-linked
immunosorbent assay (ELISA) to determine whether there is sig-
nificant cross-reactivity between antibodies against GAS or CX
and cardiac proteins.
MATERIALS AND METHODS
SIMILARITY SEARCHES
Two alignment methods, BLAST (70) and LALIGN (71), were
employed to search for similarities between microbial and car-
diac proteins. Both methods are limited to searching for linear
epitope similarities, which will miss three-dimensional conforma-
tional similarities and possible cross-reactivities between protein
and non-protein epitopes. Since most (though certainly not all)
MM is likely to involve T-cell mediation, and T cells generally rec-
ognize linear peptides 8–20 amino acids in length, these limitations
seem acceptable for the present study. Moreover, since both pro-
grams were designed to reveal evolutionary relationships rather
than immunological ones, an additional criterion was imposed
on all of the results, which was that any similarity had to involve
at least 5 identical amino acids in a sequence of 10 and prefer-
ably additional identities or reasonable amino acid substitutions.
Previous experiments have demonstrated that this 5-of-10 rule
has good predictive value for identifying cross-reactive peptide
epitopes (72, 73).
BLAST 2.0 (www.expasy.org) was used to explore the overall
degree of similarity between the microbes and proteins shown in
Tables 1 and 2. The BLAST parameters were set on the maxi-
mum values for the E threshold (10000), number of best scoring
sequences to show (3000), and number of best alignments to show
(1000); gapped similarities were permitted and the low complexity
filter was turned off. Data on the number of similarities having 6
or more identities in a sequence of 10 amino acids and the number
of sequences that had E values (a function measuring the proba-
bility of any two sequences in the protein database of equal length
having an equivalently good match) greater than 60 were tabulated
(Tables 1 and 2). The choice of these identity and E values clearly
distinguished between proteins that had high degrees of similarity
and those that did not.
The results of the BLAST search was refined using LALIGN
(www.expasy.ch), which permits better targeted similarity
searches, and these results were used to investigate the specific
regions of the proteins involved in potential epitope similarities.
The LALIGN parameters were set on the maximum number of
alignments (20) using BLOSSUM80 leaving all other settings were
in default mode. The results of the LALIGN searches are shown in
Figures 1–5.
EXPERIMENTS
Three types of experiments, ELISA, double-antibody ELISA (DA-
ELISA), and Ouchterlony immunodiffision, were employed to
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Table 2 | Summary of BLAST 2.0 similarity searches comparing human proteins (left) with each other (top).
Myo 6 Myo>60 Act 6 Act>60 Col1 6 Col1>60 LS-4 6 LS-4>60 Tro 6 Tro>60
Actin 2 0 0 0 0 0 1 0
Collagen I 2 0 0 0 10 1 0 0
Collagen IV 3 0 2 1 * * 12 2 1 0
Troponin 6 3 1 0 0 0 3 1
Myosin 2 0 2 0 3 4 6 3
Laminin 1 6 12 0 0 10 2 * * 2 1
Laminin 2 4 22 4 0 24 20 * * 6 0
Laminin 3 7 21 3 0 16 4 * * 2 0
Laminin 4 22 10 0 0 9 1 3 1
Laminin 5 5 16 7 0 12 10 * * 9 1
CD55 3 0 0 0 3 0 1 0 0 0
CXAR 2 0 0 0 0 1 4 0 0 0
PVR 0 0 0 0 1 0 0 0 0 0
CD81 1 0 0 0 0 0 0 1 1 0
CLDN1 0 0 0 0 3 0 2 0 1 0
CD20 5 0 0 0 2 0 2 0 1 0
Myo stands for cardiac myosin; Act for actin; LS-4 for laminin type 4; andTro for troponin.The meanings of the “6” and “>60” are the same as inTable 1, as are the
highlights.
investigate whether the similarity searches yielded immunologi-
cally valuable information.
Enzyme-linked immunosorbent assay (ELISA) was used to
investigate cross-reactivities between microbial antibodies and
cardiac tissue-related proteins. The tissue protein was diluted in
pH 7.4 phosphate buffer to a concentration of 10µM. This stan-
dard solution was then diluted by 10-fold steps to about 10−14 M.
Two wells received only phosphate buffer as controls. 100µL of
each protein dilution was added in duplicate to wells of a Costar
round-bottomed 96-well ELISA plate and incubated for 1 h. The
excess protein triply washed out using a 1% Tween 20 solution
(in phosphate buffer) and a plate washer. Next, 200µL of block-
ing agent (2% polyvinylalcohol in phosphate buffer) was added
to every well, incubated for an hour, and then triply washed. An
antibody against a microbe (at 1 mg/mL concentration) was then
diluted to 1/200 in phosphate buffer and 100µL added to every
well. The antibody was incubated for an hour and then triply
washed. A species-appropriate horseradish peroxidase-linked sec-
ondary antibody was then at a dilution of 1/1000, incubated for an
hour, and triply washed. Finally, 100µL of ABTS reagent (Chemi-
con) was added, incubated for 30 min, and the plate read at 405 nm
in a Spectramax UV-VIS scanning spectrophotometer. Data were
gathered using Spectramax software and then analyzed using
Excel. Analysis essentially consisted of subtracting non-specific
binding to the buffer-only wells from the protein-containing wells
and plotting the amount of antibody binding (as measured by
absorbance at 405 nm) as a function of protein concentration.
Double-antibody ELISA was used to investigate possible anti-
genic complementarity between the antibodies used in the study.
DA-ELISA differs from ELIAS in that the protein laid down in n
the 96-well plate in the initial step of an ELISA is substituted with
an antibody. A second antibody (from a different species) is tested
for its ability to bind to the first. The ability of the second antibody
to bind to the first is then monitored using peroxidase-linked
antibody against the species from which the second antibody is
derived (74–77). As in the ELISA protocol, the first antibody is
made up at a concentration of about 10µM (assuming IgG anti-
bodies have a molecular weight of 180,000 daltons) and then
serially diluted by factors of 10. The rest of the protocol is the
same.
Finally, since DA-ELISA is limited to testing whether antibodies
from different species interact, Ouchterlony immunodiffusion was
used to determine whether pairs of monoclonal antibodies might
recognize each other as antigens (75, 76). A 2.5% agarose gel was
made using distilled, deionized water; the gel was plated on sterile
microscope slides; when the gel had set, holes were punched in the
gel using a template; and 30µL of each monoclonal antibody was
added to each well. The slides were checked for precipitation lines
after 24 h.
ANTIBODIES
Group A Streptococcal antibodies
Pierce GAS monoclonal antibody MA1-10698; Pierce GAS mon-
oclonal antibody MA1-10699; Pierce GAS monoclonal anti-
body MA1-10700; Pierce GAS monoclonal antibody MA1-10701;
MyBioSource Group A Streptococcus monoclonal antibody
MBS190189; Rabbit anti-Streptococcus group A-HRP antibody
(AcrisBP2026HRP).
Coxsackie antibodies and antisera
Millipore Ms x Coxsackie Virus B3 MAB948; USBiological Ms x
Coxsackie Virus B3 MAb C7904-91E; USBiological Ms x CX B1-6;
Biorbyt Ms x Coxsackie Virus B3 orb79434; Horse anti-coxsackie
B3 virus antiserum (NIH ATCC); Monkey anti-coxsackie B4 virus
antiserum (NIH ATCC).
Protein antibodies
Rabbit anti-actin antibody (Sigma A2668); Rabbit anti-laminin
antibody (Sigma L9393); Goat anti-cardiac myosin (Santa Cruz
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FIGURE 1 | Results of LALIGN similarity search comparing coxsackie B3 virus (P03313) to human collagen IV (P02462).
Biotechnology sc-12117); Rabbit anti-collagen IV (Novus Biolog-
icals NB120-6586).
Secondary antibodies
Goat anti-mouse IgG-HRP antibody (Sigma A9917); Goat
anti-rabbit-HRP (Sigma A0545); Goat anti-human IgG-HRP
(Chemicon AP120P); Goat anti-horse HRP (Biodesign
W99260P).
Proteins
Myosin, calcium activated from porcine heart (Sigma-Aldrich
MO531); Actin from rabbit muscle (Sigma-Aldrich A2522);
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FIGURE 2 | Results of LALIGN similarity search comparing coxsackie
B3 virus (P03313) to the extracellular regions of the cardiac human
beta 1 adrenergic receptor (B1AR) (P08588). GAS M proteins, notably,
have no sequence similarity with B1AR.
Human Fibronectin (Cultrex); Human Collagen I (Cultrex);
Human Collagen IV (Cultrex); Mouse Laminin 1 (Cultrex);
Human Vitronectin (Cultrex).
RESULTS
Significant molecular and antigenic mimicry between myosin
and the M protein of GAS (1, 30, 31) and between cardiac
actin and CX (40) has been reported previously and the BLAST
and LALIGN similarity searches strongly confirm these previ-
ous reports (Table 1). One question addressed in this research is
whether GAS and CX have significant similarities to other cardiac
proteins, particular extracellular ones, that might explain the car-
diotropic effects of GAS- and CX-related autoimmune disease.
Such similarities do exist using two measure of similarity, num-
ber of sequences that share 6 or more identical amino acids out
of 10, and the number of shared sequences that have E scores of
60 or above (indicating statistically significant sequence similarity
over extended stretches). A BLAST 2.0 search of GAS and CX pro-
teins against various human cardiac proteins yielded the results
summarized in Tables 1 and 2. Table 1 shows that CX mimics
cardiac actin, collagens, myosin, and some laminins but not tro-
ponin or a variety of receptors such as the CAR, the poliovirus
receptor, etc. The M protein of GAS shares, as expected from previ-
ous studies, many significant sequences with cardiac myosin, and
also with laminins, but with no other proteins studied. Table 2
demonstrates that the GAS similarities to myosin and laminins
are reflected in very significant similarities between myosin and
laminins themselves. Myosin also shares some sequence similarity
to troponin. Collagens I and IV share significant sequence similar-
ities with some laminins as well. BLAST similarity searches there-
fore suggest that MM extends beyond myosin-GAS or actin-CX to
include extracellular matrix proteins.
LALIGN similarity searches, which are more targeted than
BLAST searches, identified many individual regions of similarity
between the various proteins tested in this study. Significant sim-
ilarities were defined by the presence of at least 5 identical amino
acids in a sequence of 10, and counting every pair of acceptable
amino acid substitutions as an identity. While more than a dozen
significant similarities were found between actin and CX proteins,
these are not illustrated here as some of them have been published
previously (40). Figure 1 shows that CXB3 also has many signifi-
cant similarities to collagen IV. It follows both logically and eviden-
tially, that cardiac actin and collagen IV also share many significant
similarities and these, too, were observed (data not shown). Thus,
CX, actin, and collagen IV share potential epitope mimicry among
themselves. CX also mimics several of the extracellular sequences
of the B1AR (Figure 2), which has been identified as a target of
autoantibodies in dilated cardiomyopathy (56–59).
LALIGN studies revealed a similar set of potential epitope mim-
ics among GAS, myosin, laminin, and the CAR. Cunningham
(1, 30, 31) has already established the very significant sequence
similarities and cross-reactivities between GAS M protein and
cardiac myosin, so data pertinent to that fact have been omitted
here. Surprisingly, laminins also share very significant sequence
similarities to GAS M protein (Figure 3 illustrates the data for
laminin alpha 1 only, but other laminins share similarly significant
regions). In addition, laminins share very significant similarities
with human cardiac myosin (again illustrated only with laminin
alpha 1 data in Figure 4). Even more surprisingly, CAR shares
potential epitope similarities with laminins (data not shown),
GAS M protein (Figure 5A), and cardiac myosin (Figure 5B).
Thus, it is possible that CAR is a target of the anti-GAS, anti-
myosin, and anti-laminin antibodies that are known to accompany
RHD/AM.
ELISA was used to test whether the BLAST and LALIGN results
translate from sequential similarities to actual antibody cross-
reactivities. Table 3 summarizes the results of the studies carried
out here, which investigated cross-reactivities between anti-GAS
and anti-CX antibodies and extracellular matric proteins, but not
the beta 1 adrenergic receptor or CAR, which were not readily
available in the quantities necessary for such experiments. In gen-
eral, antibodies raised against a protein target yield dissociation
constants in the 10−12 M range in these studies, whereas dissoci-
ation constants due to cross-reactivity between antibodies raised
against one protein that recognize another may range between
10−11 and 10−6 M. Those cross-reactivities that have dissocia-
tion constants less than 10−9 have been highlighted in Tables 3
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FIGURE 3 | Results of LALIGN similarity search comparing group A streptococcal M protein (P08089) to human laminin alpha 1 (P25391).
and 4 as having the greatest probability of being of pathological
significance.
In summary, while several antibodies against GAS had little
or no significant cross-reactivity to any of the proteins tested,
three monoclonal antibodies against GAS were identified that
bound with significant affinity to both myosin and laminin.
These antibodies generally had much less affinity for actin, col-
lagens, fibronectin, and vitronectin. Some of the experimental
data from these experiments are illustrated in Figures 6 and 7.
These data suggest that GAS can induce antibodies that cross-react
with laminins and that some of these antibodies recognize both
laminins and myosin. These data are in accord with the BLAST
and LALIGN results reported above.
Antibodies against CX raised in horses and monkeys, in con-
trast to those against GAS, had less affinity for laminin and myosin
and more for actin, collagen IV, and fibronectin. Since CX anti-
body binding to actin has been documented elsewhere (40), those
data are not illustrated here. A monoclonal antibody against CXB3
had primary affinity for myosin and little affinity for any of the
other proteins tested. The binding of these CX antibodies to col-
lagen IV is illustrated in Figure 8. These data suggest that CX
can induce antibodies that cross-react with actin and collagen IV
www.frontiersin.org August 2014 | Volume 2 | Article 85 | 7
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FIGURE 4 | Results of LALIGN similarity search comparing human laminin alpha 1 (P25391) to human cardiac myosin (P13533).
and, potentially, with fibronectin as well. Again, these results fit
well with the predictions made from BLAST and LALIGN above.
These data are summarized in Table 3.
Several lines of reasoning involving molecular complementar-
ity led to a further set of experiments. Both actin and myosin are
targets of autoantibodies in RHD/AM and actin and myosin bind
to each other through molecular complementarity. Both laminins
and collagen IV are targets of autoantibodies in RHD/AM and
laminin binds to collagen IV through molecular complementar-
ity. GAS mimics laminins and myosin, while CX mimics actin and
collagen IV, suggesting that GAS may have antigenic epitopes com-
plementary to those of CX. In order to test whether such antigenic
complementarities exist, DA-ELISAs were run in which the antigen
in a typical ELISA is replaced with an antibody. Figure 9 shows that
four of the monoclonal antibodies against GAS used in these stud-
ies bind with significant affinity to Horse x CXB4 antibodies, with
a K d of about 10
−10 to 10−11. The same GAS antibodies bound to
monkey CXB3 with K d’s of about 10
−8 to 10−9 (data not shown).
Several monoclonal antibodies against CX antigens were explored
for binding to the GAS monoclonal antibodies using Ouchterlony
immunodiffusion, but without success (Table 4), demonstrating
that the GAS-CX complementarity involves specific, but as yet
unidentified, antigens.
We have previously demonstrated similar binding between
polyclonal GAS antibodies and the CX antibodies utilized here as
well as anti-myosin antibody binding to CX antibodies (40). Since
the BLAST and LALIGN similarity searches demonstrated signif-
icant mimicry between GAS M protein and laminin, and since
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FIGURE 5 | (A) Results of LALIGN similarity search comparing human coxsackie and adenovirus receptor (CAR) (P78310) to group A streptococcal M protein
(P02977); and (B) results of LALIGN similarity search comparing human coxsackie and adenovirus receptor (CAR) (P78310) to human cardiac myosin (P13533).
Table 3 | Results of ELISA experiments involving GAS (group A streptococcus) and CX (coxsackie virus) antibodies binding to the proteins listed
along the top.
Laminin Myosin Actin Collagen IV Collagen I Fibronectin Vitronectin
GAS MA1-10698 (62) 2×10−9 2×10−10 2×10−6 1×10−7 4×10−9 1×10−6 3×10−8
GAS MA1-10699 (64) >10−5 >10−5 >10−5 >10−5 >10−5 >10−5 >10−5
GAS MA1-10700 (65) 8×10−6 3×10−10 >10−5 3×10−7 >10−5 1×10−7 >10−5
GAS MA1-10701 (66) >10−5 >10−5 >10−5 >10−5 >10−5 >10−5 >10−5
GAS Mab MBS190189 4×10−9 3×10−8 >10−5 >10−5 1×10−7 4×10−8 >10−5
GAS Rabbit-HRP >10−5 >10−5 >10−5 >10−5 >10−5 >10−5 >10−5
CXB4 Horse 3×10−7 3×10−8 2×10−9 1×10−11 1×10−6 >10−5 >10−5
CXB3 Monkey >10−5 3×10−8 7×10−10 2×10−9 >10−5 8×10−10 >10−5
CXB3 MAB948 1×10−7 5×10−8 >10−5 >10−5 >10−5 1×10−6 >10−5
Anti-laminin Rabbit 7×10−12
The numbers represent the binding constants of the antibodies to the proteins using the inflection point of the binding curves as an approximation of the binding
constants (see Figures 10 and 11). The smaller the binding constant, the greater the affinity of the antibody for the protein. Rabbit anti-laminin binding to laminin is
provided as a reference for the binding expected of an antibody to the target against which it was raised.
laminin is very similar to myosin as well, GAS antibodies were
replaced with anti-laminin antibodies in the next set of experi-
ments. Anti-laminin antibodies also bind to CX antibodies with
reasonably high affinity (K d’s of approximately 10
−9 to 10−10 M)
(data not shown). These data therefore demonstrate that CX anti-
gens are complementary to GAS, myosin, and laminin antigens.
This interpretation of the data is strengthened by the fact that
laminin antibodies precipitate collagen IV antibodies in Ouchter-
lony immunodiffusion experiments (data not shown), as would
be expected since collagen IV mimics some CX antigens (Figure 1,
LALIGN data above).
The antibody specificities and antibody–antibody interactions
were subject to a wide range of control experiments, the results of
which are summarized in Tables 3 and 4. These controls demon-
strate that the sets of cross-reactions and interactions are quite
specific, the majority of control experiments yielding no measur-
able binding of the antibodies to proteins that are not major targets
in RHD/AM.
To summarize, BLAST 2.0 and LALIGN search results demon-
strate very significant similarities between the M protein of GAS,
cardiac myosin, and laminins and also between CX proteins, car-
diac actin, and collagen IV but not between GAS or CX and most
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Table 4 | Results of double-antibody (DA)-ELISA experiments and Ouchterlony immunodiffusion experiments involving GAS (group A
streptococcus) antibodies binding to CX (coxsackie virus) antibodies.
HS CXB4 MN CXB3 CXB1-6 MA CBXB3 MAB1 CXB3 MAB2 CXB3 MAB3
GAS MA1-10698 (62) 4×10−11 5×10−9 0 0 0 0
GAS MA1-10699 (64) 6×10−11 6×10−9 0 0 0 0
GAS MA1-10700 (65) 8×10−11 4×10−9 0 0 0 0
GAS MA1-10701 (66) 3×10−11 5×10−9 0 0 0 0
GAS Mab MBS190189 5×10−10 1×10−7 0 0 0 0
GAS Rabbit-HRP >10−5 >10−5 0 0 0 0
Goat anti-Horse-HRP 1×10−12
Numbers represent the approximate binding constants of the antibodies for each other assuming a molecular weight of 180 kD for IgG antibodies and an average
of one-to-one binding between antibodies. No pair of monoclonal antibodies (MA or MAB) precipitated each other in the Ouchterlony immunodiffusion experiments.
Goat anti-Horse–Horseradish peroxidase-linked antibody binding to horse antibodies is provided as a reference for the binding affinity expected of an antibody to the
target against which it was raised.
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FIGURE 6 | Results of ELISA experiments involving monoclonal
antibodies against group A streptococci (GAS MAB) binding to
myosin. Binding constants forTable 3 were derived from the inflection
points of the curves.
other extracellular proteins or between myosin or actin and other
extracellular proteins. Laminin also mimics the CAR, which mim-
ics M protein and myosin as well. The cross-reactivities displayed
in vitro by antibodies to GAS, CX, myosin, actin, collagen IV, and
laminin are consistent with the BLAST results. Anti-GAS MAbs
that recognize myosin also recognized laminin. Anti-CX antibod-
ies have, instead, greater specificity for both actin and collagen IV.
In other words, the M protein of GAS mimics both extracellular
laminin and intracellular myosin, while CX proteins mimic both
extracellular collagen IV and intracellular actin. Possible cross-
reactivity between antibodies to CX and the B1AR and between
antibodies to GAS and CAR are also possible.
DISCUSSION
PLACING THE RESULTS IN THE CONTEXT OF THE CLINICAL AND
EXPERIMENTAL LITERATURE
The in vitro findings described in the Section“Results”broaden the
set of host antigens that are likely targets in RHD and AM beyond
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FIGURE 7 | Results of ELISA experiments involving monoclonal
antibodies against group A streptococci (GAS MAB) binding to
laminin 1. Binding constants forTable 3 were derived from the inflection
points of the curves.
myosin and actin to include extracellular proteins associated with
GAS and CX binding. These in vitro results are consistent with
in vivo experimental and human clinical observations that have
found autoantibodies against laminin, collagen IV (but not col-
lagen I), B1AR, and CXAR as well as against myosin and actin
in RHD and AM (39, 60–62, 78–85). In some cases, these anti-
bodies recognize both laminin and cardiac myosin, mimicking the
cross-reactivity observed in vitro here (81).
These clinical results support the extrapolation of the present
results to understanding RHD/AM pathogenesis and permit some
novel predictions to be made. Since extracellular matrix proteins
are also molecular mimics of myosin, actin, GAS, and CX pro-
teins, MM is much more widespread than previously thought.
Specifically, laminin mimics GAS M protein and is recognized by
some GAS antibodies; collagen IV mimics some CX proteins and
is recognized by CX antibodies. In addition, laminin mimics car-
diac myosin and laminin antibody recognizes myosin; collagen IV
mimics cardiac actin and actin antibody recognizes collagen IV
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FIGURE 8 | Results of ELISA experiments involving horse
anti-coxsackie B4 serum, monkey anti-coxsackie B3 serum, or a
monoclonal (MAB) antibody against coxsackie B3 binding to human
collagen IV. The downward turn of the curves at high concentrations of
collagen IV suggest that collagen IV self-aggregates, hiding the binding sits
from antibody. Binding constants forTable 3 were derived from the
inflection points of the curves.
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FIGURE 9 | Results of double-antibody ELISA (DA-ELISA) experiments
involving monoclonal antibodies against group A streptococci (GAS
MAB) binding to horse anti-coxsackie B4 serum. Binding constants for
Table 4 were derived from the inflection points of the curves. Note that two
of the antibodies also display a second, low affinity binding to each other at
high concentrations of CX antiserum. Very similar results were obtained for
group A streptococci (GAS MAB) binding to monkey anti-coxsackie B3
serum (data not shown).
as an antigen. Among the possibilities that these results raise is
that laminin is one of the receptor proteins used by CX to target
cardiac tissues. Such a possibility is consistent with Orthopoulos
et al.’s (68, 69) results showing that at least five, as yet unidentified,
extracellular proteins besides CAR and DAF/CD55 are utilized
by CX as receptors. Similar reasoning leads to the suggestion
that GAS may utilize the beta 1 adrenergic receptor (B1AR) as a
receptor, since B1AR mimics the already-identified GAS receptor
collagen IV.
Recognition that molecular (or epitope) mimicry is more wide-
spread in RHD/AM helps to resolve one problem – how intracel-
lular proteins such as myosin become targets in RHD/AM – but
exacerbates another, which is that laminins, collagens, and even
DAF and CAR are fairly widespread proteins that are certainly
not limited to cardiac tissue. So how do infections with GAS
or CX result specifically in RHD or AM rather than some other
autoimmune disease?
While genetic predisposition is probably one reason that some
people are more susceptible to RHD/AM than others [e.g., (7,
29)], animal models of these diseases provide additional clues
as to what produces autoimmune disease susceptibility. In all
existing animal models of RHD and AM, even in susceptible
strains of animals, the “causative” agents must always be accompa-
nied by appropriate “adjuvants.” The M protein of GAS requires
FCA (86); allogeneic myosin requires FCA (53, 87); CX requires
either FCA boosted with pertussis or CX inoculated with car-
diac alloantigens (28, 88, 89). CX passaged on tissues other than
heart tissue does not produce EAM. Where FCA is required, no
other adjuvant can be substituted (86). Use of incomplete Fre-
und’s adjuvant (IFA) with myosin or M protein results only in
transient myocardial inflammation, but not autoimmunity (90).
Models of EAM produced by inoculating rodents with cardiac
actin or cardiac c protein require instead of FCA the use of Kleb-
siella pneumoniae O3 lipopolysaccharide (LPS) (91, 92). Neither
actin nor c protein will produce EAM by themselves. Substitu-
tion of K. pneumoniae O3 LPS with LPS derived from other
Klebsiella species, Escherichia coli, and Salmonella also fails to
produce EAM (91, 92). Timing of adjuvant administration is
also critical, as inoculating animals with FCA several days or
weeks prior to the myocarditic mixture prevents EAM (93). In
other words, every animal model of RHD and AM requires some
concurrent combination of antigens, not a single, simple molec-
ular mimic. Such concurrent combinations may be an important
clue to the natural etiologies of RHD and AM: the difference
between uncomplicated GAS or CX infections and those that
go on to induce chronic autoimmune disease might be that the
presence of specific co-infections that act as “adjuvants” for GAS
or CX (40, 94).
Epidemiological studies of RHD and AM suggest that those
people who develop autoimmunity do differ in having co-
infections from those people who do not develop autoimmunity,
who are characterized by uncomplicated monoinfections. Epi-
demiological studies demonstrate that 80–100% of RHD cases
occurred when CX infection was present concurrently, while
uncomplicated GAS infection was almost never associated with
development of RHD (95–97). Conversely, 65–80% of AM cases
that present with CX infection were complicated with a concurrent
GAS infection (32, 98, 99). Moreover, AM patients differ signifi-
cantly from patients with uncomplicated monoinfections with a
variety of viruses and bacteria in producing T cell receptors (TCR)
against both CX and GAS (48). In addition, between 12 and 42%
cases of AM are associated with multiple, concurrent viral infec-
tions (11, 14, 100) often involving CX, parvovirus B19, and HHV6.
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FIGURE 10 | Illustration of the ways in which molecular mimicry
between coxsackie virus antigens (CX) and/or group A streptococci
(GAS) antigens and extracellular proteins of cardiomyocytes may result
in the production of autoantibodies. CX uses the coxsackie and adenovirus
receptor (CAR) as well as the complement decay-accelerating (DAF or CD55)
protein as receptors to target cardiomyocytes. Some CX proteins mimic
collagen IV as well as the beta 1 adrenergic receptor (B1AR, not shown), so
that anti-CX immune responses may also target collagen IV and B1AR. GAS
uses collagen IV and various other cardiac proteins as receptors. The M
protein of GAS mimics laminins so that antibodies against GAS may also
target cardiac laminins. In addition, GAS M protein and laminins share epitope
similarities with CAR, so that CAR may be an additional target of GAS
antibodies. Note that although the illustration shows antibodies, the same
sets of interactions could occur with T cell receptors (TCR).
Possible bacterial co-infections such as GAS were not considered
in these viral studies and may also have been present.
BEYOND MOLECULAR MIMICRY TO ANTIGENIC COMPLEMENTARITY
There are several ways in which co-infections may play crucial
roles in transforming a simple GAS or CX infection into one that
induces autoimmune disease. To begin with,each infection may act
as an “adjuvant” for the other, each initiating an immune response
that induces localized cytokine release at the site of co-infection.
The resulting synergy would produce the so-called “bystander
effect” that has been postulated to work in conjunction with MMT
to initiate release of alloantigens and to produce autoimmune dis-
ease. Such co-infections might also alter the Th1/Th2 balance.
It appears that uncomplicated infections tend to produce a Th2
response, whereas a shift toward a Th1 response is more likely to
result in autoimmunity [e.g., (29, 101)]. One of the key roles played
by adjuvants in animal models of RHD and AM is to shift the
immune response toward a Th1 mode (102–104). Co-infections
may also produce synergistic effects that can promote autoim-
munity (105, 106). In fact, animals co-inoculated with GAS and
CX are far more likely to develop severe carditis than are animals
inoculated with either pathogen separately (99, 107).
The possibility that GAS and CX act synergistically (and that
other co-infections may do so as well) opens up a new possibility
that extends MM to antigenic complementarity. Root-Bernstein
has demonstrated that GAS induces antibody responses that are
complementary to CX antibodies, so that the two sets of idio-
typic antibodies act like an idiotype–anti-idiotype pair (40). This
antigenic complementarity is further mirrored in the induction
of pairs of complementary TCR that mimic both GAS and CX
antigens (48). The complementarity of the antigens presented by
CX and GAS to the immune system is mirrored in the molecular
complementarity of some of the key extracellular host proteins
found in this study. GAS mimics laminin, CAR, and myosin while
CX mimics collagen IV. CAR and CX are molecularly comple-
mentary, CX using CAR as a receptor. GAS and collagen IV are
complementary, GAS using collagen IV as a receptor. Laminin and
collagen IV are themselves molecularly complementary. Laminin
binds specifically to collagen IV to form the fundamental structure
of the basement membrane (108–114) and this self-assembly can
be interrupted by antibodies against either laminin or collagen IV
resulting in failure of the integrity of the membrane (112). Actin
(which is an epitope mimic of CX) and myosin (which is an epi-
tope mimic of GAS) are also molecularly complementary; actin
and myosin bind to each other to form the actomyosin complex
essential to contractile muscle function (115–117). The fact that
GAS is antigenically complementary to CX, that laminin is com-
plementary to collagen IV, that myosin is complementary to actin,
and that all six are known targets of autoantibodies in RHD/AM,
suggests that beyond MM, the role of antigenic complementarity
in the pathogenesis of autoimmune forms of carditis must also be
considered.
A NEWMODEL OF RHD/AM PATHOGENESIS
The extension of MM to extracellular proteins and the incorpo-
ration of antigenic complementarity suggest a new explanation
of RHD/AM pathogenesis that is illustrated in Figures 10 and
11. Infections with either GAS or CX localize at cardiomyocytes
Frontiers in Pediatrics | Pediatric Cardiology August 2014 | Volume 2 | Article 85 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Root-Bernstein Rethinking molecular mimicry
FIGURE 11 | (A) Illustration of the destructive effects that antibodies from
Figure 10 would have on cardiomyocytes. Autoantibodies against GAS and/or
CX would target basement membrane proteins such as laminin and collagen
IV and possibly cardiomyocyte receptors such as CAR and B1AR.
Cardiomyocyte membrane integrity would be compromised permitting
antibodies to move on to target actin, myosin, and other hidden antigens.
Because of the molecular mimicry between the GAS M protein, laminins,
CAR, and myosin, epitope drift would result in a range of immune responses
against all four. Similarities between CX epitopes, collagen IV, B1AR, and actin
would lead, through epitope drift, to the similar evolution of the immune
response from the pathogen to the cell membrane to hidden antigens inside.
Note again, as in Figure 10 that although this process is illustrated with
antibodies, the same sets of interactions could be mediated through TCR.
(B) Antigens on GAS, especially the M protein, mimic laminins, myosin, and
the coxsackie and adenovirus receptor (CAR). Antigens on coxsackie viruses
(CX) mimic collagen IV and actin as well as the beta 1 adrenergic receptor
(B1AR – not shown). In consequence, antibodies against CX also recognize
collagen IV and actin (and possibly B1AR, not yet demonstrated), while
antibodies against GAS M protein also recognize laminin, myosin, and possibly
CAR, not yet demonstrated. It also follows that antibodies against GAS are
complementary to antibodies against CX, so that anti-CX mimics GAS,
laminin, myosin, and CAR; and antibodies against CX are complementary to
antibodies against GAS, so that anti-GAS mimics CX epitopes, collagen IV,
actin, and possible B1AR. The antigenic complementarity of GAS for CX will
therefore lead their antibodies to precipitate each other and to form circulating
immune complexes involving GAS and CX proteins as well as the entire range
of host protein targets. The immune system will be unable to distinguish
“self” from “non-self” leading to abrogation of tolerance and the induction of
autoimmune disease. Note once again that the same consequences would
occur for T-cell mediated responses as are illustrated here for antibodies.
producing an immune response that cross-reacts with laminin
and/or CAR (in the case of GAS) or collagen IV and/or B1AR
(in the case of CX) (Figure 10). Damage to the extracellular
matrix destabilizes cardiomyocyte structure permitting myosin
and actin to be released (Figure 11A). Anti-GAS antibodies and
T cells cross-reactive with laminins and/or CAR, in turn, begin
to target the more antigenic cardiac myosin. Anti-CX antibod-
ies and T cells cross-reactive with collagen IV and/or B1AR will
begin to target the more antigenic actin. Even after GAS and CX
infections are eliminated, their antibodies and T cells will con-
tinue to be stimulated by the presence of an ongoing supply
of both extracellular and intracellular “self” proteins. Thus, the
immune response evolves from GAS-CX to laminin-collagen to
myosin-actin through epitope drift.
To this point, it is possible to interpret Figures 10 and 11A as if
either GAS or CX can independently induce autoimmunity against
heart tissue, but such a model does not explain what makes a GAS
or CX infection that does not lead to autoimmune disease different
from one that does; cannot account for the rarity of autoimmune
disease following GAS or CX infections; and cannot account for the
need of “adjuvants” (or perhaps some sort of hyperinflammation)
in animal modes of RHD and AM. It is proposed that these dif-
ficulties can be addressed by assuming that autoimmune disease
only follows combined infections of GAS with CX (or perhaps
with other combinations of cardiotropic pathogens), as is consis-
tent with both human epidemiology and the animal experiments
of Kogut et al. (99) and Pearce (107). Thus, it is possible to re-
interpret Figures 10 and 11A as showing what might happen
if GAS and CX were present simultaneously. Figure 11B then
explores some of the unique consequences of such a combined
infection.
If both GAS and CX are present simultaneously, rather than as
independent infections, unique consequences ensue (Figure 11B).
In the first place, the anti-GAS immune response (whether anti-
body or T cell) will be antigenically complementary to the anti-CX
immune response (antibody or T cell). The resulting antibod-
ies and/or T cells will act like idiotype–anti-idiotype pairs, even
though each response has been initiated as an idiotypic one. These
complementary immune responses will do several unusual things.
First, they will neutralize each other forming immune complexes
and stimulating a hyperinflammatory response. This hyperinflam-
matory response will take place specifically at the cardiomyocyte
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cell matrix and at the GAS and CX cardiomyocyte receptors
(Figure 10). Not only will the immune system be less able to
clear the co-infection of GAS-CX due to co-neutralization of the
immune responses, but the hyperinflammation will cause excess
cardiac damage, further driven by release of hidden antigens such
as myosin and actin (Figure 11A). Notably, circulating immune
complexes (CIC) will be formed that are composed not only both
sets of antibodies but also any of the GAS, CX, and cardiac anti-
gens that may be present (Figure 11B). These CIC will stimulate
further damage not only at heart tissue but also in the liver and
kidneys.
Most importantly, this new model provides a specific mecha-
nism by which the distinction between “self” and “non-self” can
be abrogated. When the immune system having to process two
antigenically complementary pathogens, each of which mimic
complementary “self” proteins, the result is the production of
complementary immune responses (antibody and/or T-cell medi-
ated) each of which mimics host proteins as well as one of the
pathogens. The immune system becomes “confused,” tolerance
must be abrogated in order to respond to the pathogens, and
autoimmune disease follows.
The model is both clinically and experimentally testable. Clini-
cally, it should be found that people who develop RHD/AM differ
from those with uncomplicated GAS or CX infections in either
having both infections simultaneously, of having some other com-
bination of co-infections that are cardiotropic. Experimentally, it
should be possible to induce experimental forms of RHD and
AM using a combination of GAS-CX infection, or even by using
inactivated GAS with inactivated CX. Passive transfer of experi-
mental RHD/AM should be achievable by infecting one group of
rodents with GAS, another with CX and then transferring antibod-
ies and/or T cells from both groups to a single set of recipients.
The mono-infected animals should not develop RHD/AM, but
the recipients of the combined GAS-CX antibodies and/or T cells
should develop autoimmune disease.
CONCLUSION
In sum, broadening the view of molecular (epitope) mimicry in
RHD/AM beyond myosin and actin suggests a model of pathogen-
esis that accounts not only for the experiments and observations
stemming from MMT but also for the much broader set of data
that MMT cannot explain. RHD and AM are rare despite the fre-
quency of GAS and CX infections because each pathogen requires
an antigenically complementary co-infection, which is often each
other. Combining an extended form of MM with antigenic com-
plementarity also provides a specific mechanism by which toler-
ance can be broken and the specific set of autoantigens that are
subsequently targeted explained, which MMT cannot do by itself.
It is worth noting that the model suggested is predicated on
a significant departure from Koch’s postulates. Koch’s postulates
have, of course, been the standard for demonstrating disease cau-
sation for more than a century but assume that each disease has a
single pathogenic cause. The proposition that RHD, AM, and per-
haps other autoimmune diseases are due to specific combinations
of pathogens runs contrary to the isolation of the single“causative”
agent of disease. A multifactorial set of “disease postulates” will be
required instead, in which it is demonstrated that more than one
pathogen is associated with an autoimmune disease, that no single
one of these pathogens can induce the autoimmune disease, but
that a combination of the pathogens does induce autoimmune
disease (48, 106, 118).
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